findmyKOL
Clinical trialNCT03894826UnknownPhase 2Interventional

Voronistat in Pediatric Patients With Drug Resistant Epilepsy

SponsorUniversity of CalgaryEnrollment12Refractory Epilepsy
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study evaluates the safety, tolerability, and efficacy of Vorinostat in addition to standard of care anti-epileptic drugs in pediatric patients with medically refractory epilepsy. All participants entering the treatment phase will receive Vorinostat.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Alberta Children'S Hospital

    Calgary, Alberta, Canada

    Deborah Kurrasch, PhDJong Rho, MDJuan-Pablo Appendino, MDLuis Bello-Espinosa, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Dec 2018
Primary completion
30 Apr 2020
Completion
31 Oct 2020
Last update posted
29 Mar 2019
Registered enrollment
12
Registry id
NCT03894826

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.